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Many females develop bone diseases such as osteoporosis, and joint diseases such as osteoarthritis after menopause when estrogen levels decline.
As estrogen receptors (ER) are present in such tissues, it is possible that the loss of estrogen at menopause influences the expression of enzymes such
as members of theMMP family of proteinases to affect bone and connective tissue metabolism. The present study was undertaken to assess a possible
relationship between ER-α and MMP-13 expression at the promoter level, and to determine how such a relationship could be modulated by ligands
such as estrogen. Using a rabbit synovial cell line lacking endogenous ER, a transient transfection system with an ER-α construct, and a series of
MMP-13 promoter-luciferase constructs of varying lengths and with specific mutations in transcription factor binding sites, it was found that ER-α
can significantly enhance MMP-13 promoter activity via the AP-1 site, with modulatory influences by the Runx and PEA-3 sites on this ER-α
dependent enhancement of the promoter activity. This enhancement by ER-α was significantly depressed in the presence of 17-ß-estradiol in a dose
dependent manner. The influence of tamoxifen and raloxifen on the activity of the ER-αwas consistent with their known agonist/antagonist activity.
These findings indicate that loss of estrogen in vivo could potentially lead to enhanced expression of MMP-13, a proteinase that has been implicated
in both osteoporosis and osteoarthritis, and thus contribute to the development and progression of these conditions.
© 2006 Elsevier B.V. All rights reserved.Keywords: OA; MMP-13; ER-α; Estrogenic ligand; AP-1 Site; Regulation1. Introduction
Osteoarthritis (OA) is a degenerative joint disease affecting
multiple joint tissues, and the incidence of idiopathic OA
increases with age. Patients with meniscal or ligament injuries
also have a higher risk for developing osteoarthritis later on in
life [1,2]. OA is characterized by the irreversible degradation
of articular cartilage. Several studies have indicated a pivotal
role for matrix metalloproteinase 13 (MMP-13) in the
pathogenesis of OA, as this enzyme effectively degrades
collagen which is the principal constituent of the cartilage [3–
5]. Elevated mRNA and protein levels for MMP-13 were
observed in cartilage, menisci and synovium following
transection of the anterior cruciate ligament (ACL) in the⁎ Corresponding author. Tel.: +1 403 220 4571; fax: +1 403 283 7742.
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doi:10.1016/j.bbadis.2006.06.007rabbit [6]. Transection of the ACL leads to the development of
OA and it is a widely used experimental technique to study the
onset and progression of this disease in rabbits and dogs [7–9].
Additionally, it has been observed that transgenic mice
overexpressing MMP-13 show evidence of degradation of
articular cartilage and exhibit joint pathology similar to those
found in OA [10]. Furthermore, studies have shown that
ovariectomy of rats leads to elevations in the expression of
MMP-13 in osteoblastic cells [11]. As females are at greater
risk for developing joint diseases such as osteoarthritis and
osteoporosis following menopause, when the estrogen levels in
the body decline [12,13], there may be a relationship between
estrogen, estrogen receptors and MMP-13.
The presence of estrogen receptors (ERs) has been established
in ligament tissues of both rabbits and human indicating that these
tissues are likely to respond to changes in levels of the hormone
estrogen (discussed in [14]). In addition, ERs have been detected
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synovium [16]. There are two main isoforms of ERs, estrogen
receptor alpha (ER-α) and estrogen receptor beta (ER-β), and
they are members of the nuclear hormone receptor family [17]. As
components of the steroid family of receptors, the ERsmediate the
effects of the ligand estrogen. The ERs form homodimers or
heterodimers in response to estrogen and subsequently bind to
hormone response elements (HRE) present in the promoters of
many estrogen responsive genes [18–20]. ERs can also effect the
regulation of the genes which lack HRE elements. In the latter
situation, the ER ligand complex can bind to transcription factors
which interact with NF-κ B sites, SP1 sites or AP-1 sites of
estrogen responsive genes [21–23]. Thus, ER–ligand complexes
can influence gene expression via multiple effects on DNA.
Recently, it has been reported that gene expression of some
extracellular matrix molecules is inhibited under the combined
effects of estrogen and mechanical loading [24].
Several studies have established the presence of bothMMP-13
and ER in joint tissues. However, it is not clear whether there
could be a regulatory relationship between the twowhich could be
influenced by the hormone estrogen. Normally, the expression of
MMP-13 is low in cells of mature joint tissues, and these low
levels allow for healthy connective tissue remodeling without
damaging the tissues [6]. In pathologic conditions, however, the
level of MMP-13 expression increases considerably, resulting in
aberrant destruction of cartilage tissue [5,6,1,25]. Based on its
importance in normal and diseased states, the regulation ofMMP-
13 expression by estrogen may provide valuable insight into the
onset and progression of OA, particularly in females. Since other
MMPs such as MMP-9 have been shown to be regulated by
nuclear receptors [26], MMP-13 is also a potential candidate for
regulation bymembers of the nuclear receptor family, in particular
ER-α. In addition, MMP-3 synthesis has been shown to be
elevated in mouse osteoblasts following the removal of estrogen
under in vitro and in vivo model systems [27].
In the present study, evidence is presented which supports a
potential relationship between ER-α and MMP-13 expression
under in vitro conditions. The effect of ER-α in the presence
and absence of different estrogen agonist and antagonistic
ligands on the regulation of the MMP-13 promoter under in
vitro conditions was also examined to assess how the ER-α/
MMP-13 relationship could be modulated by ligands. Site-
specific mutations in the transcription factor binding sites and
deletion constructs of the MMP-13 promoter were used in
transient transfection studies to assess the functionality of the
MMP-13 promoter in the presence of ER-α± ligands. The
results indicate that loss of estrogen modulation of the ER-α/
MMP-13 relationship could potentially be relevant to meno-
pause associated changes in joint tissues.2. Materials and methods
2.1. Cell culture
The rabbit synoviocyte cell line HIG-82 used in this study was obtained from
the American Type Culture Collection (Rockville, MD). Cells were grown in a
5% CO2 humidified air incubator at 37 °C in Ham's F-12 Nutrient Media (LifeTechnologies) supplemented with 10% fetal calf serum, 1% Penicillin/
Streptomycin. Cells were passaged 1:4 with 0.25% trypsin.
2.2. Isolation of rabbit MMP-13 proximal promoter
To isolate the first 637 bp of the rabbit MMP-13 promoter, total DNA was
purified from rabbit liver using the DNeasy Kit (Qiagen Inc., Mississauga, Ont.)
as directed by the manufacturer. The proximal 637 bp of the MMP-13 promoter
was obtained by amplification with PCR from purified rabbit DNA using
specific primers generated from published sequences [28]:
Forward primer 5′ CAGTGTAATGCTTTCTACCTGGA 3′
Reverse primer 5′ CTTGAATGGCCGTGCCTGGA 3′
PCR was performed for 35 cycles. The amplified 637 bp PCR fragment was
cloned directly into the pPCR-Script Amp SK(+) vector using the pPCR-Script
Amp™ cloning kit (Stratagene, Cedar Creek, TX) and sequenced to verify that
the correct fragment was obtained and to determine the orientation of the
fragment within the vector.
2.3. Construction of rabbit MMP-13 Luciferase reporter vector
The promoterless pGL2 Basic luciferase reporter vector (Promega, Madison,
WI) was used to construct a plasmid containing the proximal 637 bp of the rabbit
MMP-13 promoter. Following sequence confirmation of the promoter region, a
SacI/HindIII restriction fragment was obtained by digesting the (−637 bp—
MMP-13) pPCR-Script Amp SK(+) vector and the fragment was subcloned into
the SacI/HindIII site of the promoterless pGL2 Basic Luciferase reporter vector.
Positive clones were analysed for the presence of the MMP-13 promoter insert,
and its orientation were determined by restriction digestion and sequencing. The
resulting MMP-13 promoter-containing luciferase reporter plasmid was
designated p637-Luc. The MMP-13 promoter constructs of differing lengths
(p370-Luc, p151-Luc, p109-Luc, p73-Luc and p43-Luc) were generated by
PCR using a 5′-sense primer containing the appropriate MMP-13 promoter
sequence with a Kpn-I site introduced at the 5′-end respectively, and the same
3′-antisense primer 5′-CCAACAGTACCGGAATGCCAAGC-3′ (nucleotide 49
to 71) that corresponds to a pGL2- Basic sequence downstream of the multiple
cloning site. The 5′-primers used for p370-Luc, p151-Luc, p109-Luc, p73-Luc
and p43-Luc constructs contained MMP-13 sequence (underlined) were
−370 to –356 (5′-CGGGTACCATGGGCGTACACATA-3′),
−151 to –136 (5′-CGGGTACCTCAAATTCTACCAC-3′),
−109 to –96 (5′-GCGGTACCTGCTAAGTAAGCAT-3′),
−73 to –60 (5′-GCGGTACCAGCGGAAGCCTATT-3′), and
−43 to –30 (5′-GCGGTACCATGGCAGACCTAT-3′) respectively.
PCR products were purified and precipitated via the QIA quick-spin PCR
purification kit (Qiagen) and digested with KpnI/HindIII. The final product was
then ligated into KpnI/HindIII digested pGL2 Basic and transformed into E. coli
(DH-5α). Mutations were introduced into desired constructs using the Quick
Change Site-Directed Mutagenesis kit (Stratagene). The mutagenic oligonu-
cleotide primers were designed and synthesized for each mutant. The AP-1 site
TGACTCAwas changed by mutating T to G at the first base or TGA to ACT at
the first three bases. The PEA-3 site consensus sequence AGGAAGC was
altered to AACAAGC and the Runx domain binding sequence (RD site)
AACCACAwas changed to AGACACA. All reporter plasmids were purified on
a EndoFree Plasmid Maxi Kit (Qiagen, Mississauga, ON) according to the
manufacturer's instructions and subjected to sequencing analysis to verify the
orientation and accuracy of each construct.
2.4. Additional control and expression plasmids
The internal control plasmid pRLSV40was obtained from Promega (Promega,
Madison,WI). The pRLSV40 plasmid constitutively expresses the Renilla form of
luciferase under the strong SV40 promoter and thereby acts as an internal control in
the dual luciferase assay. The expression vector for ER-α (pKCR2-ERα) was a
generous gift from Dr. Pierre Chambon (Strasbourg, France).
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The HIG-82 cells were transfected using the FuGene6 Transfection reagent
(Roche Molecular, Indianapolis, IN) as directed by the manufacturer. HIG-82
cells were seeded on 12-well plates on the day before transfection at a density of
1×105 cells/well. The cells were washed with PBS prior to transfection and then
transfected with a constant amount (1 μg) of reporter plasmids (shown to be
optimal in preliminary studies; data not shown), pRLSV40 (50 ng) and HEGO
(0.1–4 μg in the initial experiments and 0.5 μg in the later experiments) by
means of FuGene 6 Transfection Reagent. Transfection was performed with
Ham's F-12 Nutrient Medium in the absence of serum. Immediately after
transfection, 17-β estradiol (E2) tamoxifen (Tam), and raloxifen (Ral) (All
obtained from Sigma, Oakville, ON), was added to the medium in appropriate
wells. Luciferase activity was determined in cell lysates 24 hr after transfection
using a Turner TD-20 luminometer and the Dual LuciferaseTM Reporter Assay
kit (Promega Madison, WI). All transfection experiments were repeated three or
more times with results very similar to those reported.
2.6. Immunohistochemistry and Western blotting
Immunohistochemistry and western blot were used on cells transfected with
HEGO to determine if ER protein was being expressed in transfected cells. For
these studies, the mouse monoclonal antibody mIgG1TE111.5D11 (anti-ER)
(Research Diagnostics, Flanders NJ) was used for both immunohistochemistry
of HIG-82 cells before and after transfection, and Western blotting of cellular
lysates following SDS-PAGE separation. Rabbit uterus was used as a positive
control for ER expression.
2.7. Reverse transcription-polymerase chain reaction (RT-PCR) analysis
RT-PCR was performed to determine the influence of alpha isoform of ER
(±17-β estradiol) on endogenous MMP-13 mRNA levels in HIG-82 cells
following transfection. HIG-82 cells were plated on 12-well plates on the day
before transfection at a density of 1×105 cells/well. The following day, cells were
transfected with HEGO (0.2–1.0 μg). After 24 h of transfection, cells were
washedwith PBS, and total RNAwas isolated using the TRIspinmethod [56] and
then the SYBR® Green reagent was subsequently used for fluorometric
quantification of total RNA. Total RNA (1 μg) was initially reverse transcribed
with random RT primers using a Qiagen Omniscript kit and following that rabbit
specific PCR-primers were used for amplifying the MMP-13 (5′-TTCGGCTTA-
GAGGTGACAGG-3′ and 5′-ACTCTTGCCGGTGTAGGTGT-3′) and the
housekeeping β-actin genes (5′-TGCTTCTAGGCGGACTGTTA-3′ and 5′-
CGTCACATGGCATCTCACGA-3′ from Genbank U07786) in a 40 μl reaction
as described previously [6]. Amplicons were separated on a 2% agarose gel
followed by staining with ethidium bromide. Quantity1 1-D analysis (Biorad)
software was used to determine band density. By normalizing to the levels of the
β-actin gene, relative mRNA levels for the endogenous MMP-13 gene were
determined. This experiment was performed 3× with similar results obtained.
2.8. Statistical analysis
Statistical analysis of the data was performed using ANOVA, STDEVA,
STEYX in the Excel 5.0 software.3. Results
3.1. Immunohistochemistry and Western blot analysis of ER-α
For analyzing the molecular mechanisms involved in the
possible regulatory relationship between MMP-13 and ER-α,
the effect of ER-α on the expression of a MMP-13 promoter
construct in transient transfection experiments was examined. A
rabbit synoviocyte cell line, HIG-82, was used for the trans-
fection experiments. However, prior to performing any transfec-tion experiments, the HIG-82 cell line was assessed for the
presence of endogenous ER by immunohistochemistry and
Western blot. Representative results from these experiments are
presented in Fig. 1A and B. HIG-82 cells were found to be
negative for ER using both western blot analysis (Fig. 1B, Lane
3) and immunohistochemistry (data not shown). In these
experiments, rabbit uterus was used as a positive control and
expression of ERwas readily detected with the anti-ER antibody
(Fig. 1A (Panel B) and 1B (Lane 1)). In addition, normal rabbit
synovium was found to express ER (Fig. 1B (Lane 2)). Finally,
HIG-82 cells were transfected with the pKCR2-ERα expression
plasmid and assessed by immunohistochemistry to ensure that
after transfection, the ER-α was being expressed at the protein
level in cells. As demonstrated in Fig. 1A (Panels C and D), the
HIG-82 cells originally determined to be ER negative became
ER positive after transfection with the pKCR2-ERα plasmid.
3.2. Influence of ER-α on endogenous MMP-13 mRNA levels in
HIG-82 cells
The effect of ER-α on endogenous MMP-13 mRNA levels in
theHIG-82 cellswas examined (see Fig. 2A andB). HIG-82 cells
were transfected with 0.2 μg, 0.5 μg or 1 μg of ER-α. Non-
transfected HIG-82 cells were used as a control to evaluate the
basal expression level of endogenous MMP-13. Quantity1 1-D
analysis software (Biorad) was used to determine band density
and the relative mRNA levels for the endogenous MMP-13 gene
were determined by normalizing to the levels of theβ-actin gene.
RT-PCR analysis revealed that very low constitutive levels of
MMP-13 expression are detectable in the non-transfected HIG-
82 cell line. Transfection with 0.2 μg HEGO did not lead to
significant changes in the expression of the endogenous MMP-
13 (Fig. 2A and B). However, when higher concentrations of
HEGO (0.5 and 1 μg) were used, significant increases in the
expression of endogenous MMP-13 mRNA were detected
suggesting an influence of exogenous ER-α on endogenous
MMP-13 expression levels (see Fig. 2A and B). Furthermore the
endogenous levels of MMP-13 declined when the transfected
cells were treated with 10−12 M and 10−8 M 17-β Estradiol,
suggesting a role for ligand inmodulating the influence of HEGO
on mRNA levels for the endogenous MMP-13 (data not shown).
3.3. Influence of increasing concentrations of ER-α on the
activity of the transfected MMP-13 promoter in HIG-82 cells
The HIG-82 cells were transfected with the ER-α construct
(HEGO) at concentrations of 0 μg, 0.1 μg, 0.25 μg, 0.5 μg, 1 μg,
2 μg and 4 μg to determine the effect of increasing con-
centrations of ER-α on the transfected MMP-13 promoter
construct (p370-Luc) (see Fig. 2C). The MMP-13 promoter
activity was found to increase with increasing concentration of
ER-α. In comparison to MMP-13 promoter activity in the
absence of any exogenously added ER-α, a >120-fold increase
in the activity of MMP-13 promoter was observed when 4 μg of
ER-α was used in transfections, suggesting a definite influence
of the ER-α on MMP-13. At 0.5 μg HEGO, the increase in
MMP-13 promoter activity was >50-fold. The results presented
Fig. 1. (A) Immunohistochemical analysis of rabbit uterus and HEGO transfected HIG-82 cells for the presence of expressed ER-α. Positive staining is indicated with
bright red dots. DAPI staining is in blue. (a) DAPI staining of rabbit uterus (positive control) demonstrating positive nuclear staining. (b) Detection of ERα in rabbit
uterus using antibody mIgG1TE111.5D11. (c) DAPI staining of rabbit HIG-82 synoviocytes. (d) Detection of ERα in rabbit HIG-82 synoviocytes transfected with the
HEGO expression vector. (B) Comparison of expression of ER-α protein in extracts from HIG-82 rabbit synoviocytes and synovial tissue. Western blot analysis was
performed on protein extracts from rabbit uterus, rabbit synovium and HIG-82 rabbit synoviocytes using the mouse monoclonal antibody mIgG1TE111.5D11 (anti-
ER) (Research Diagnostics, Flanders NJ). Rabbit uterus was used as a positive control in this experiment as shown in Lane A and lanes B and C exhibit the ER-α
protein levels in rabbit synovium and HIG-82 rabbit synoviocytes, respectively.
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for subsequent in vitro transfection experiments as it is likely a
more physiologic level.
3.4. ER-α modulates the activity of MMP-13 promoter
construct differently in the presence and absence of SERMs
To identify the promoter regions of MMP-13 that may play a
role in ERmediated regulation, several deletion constructs of the
MMP-13 promoter were generated and cloned into the pGL2
basic vector, which contains the promoterless luciferase reporter
gene (See Fig. 3A). The constructs p637-Luc and p370-Luc
contain all of the key elements of rabbit MMP-13 promoter
region such as the Runx domain (RD), the p53, the PEA-3 and
the AP-1 binding sites.
In the initial studies, rabbit synoviocytes were co-transfected
with the rabbit MMP-13 promoter construct (p370-Luc),
pKCR2-ERα and the internal control plasmid pRLSV40. In
the absence of any exogenous ligand, the activity of theMMP-13
promoter is high in the presence of ER-α (Fig. 3B). The effect of
the estrogenic ligand, 17-β estradiol in these transfectionexperiments was also investigated. Treatment with either 10− 8
or 10− 12 M 17-β estradiol, led to an approximately 50%
repression of the MMP-13 promoter activity (Fig. 3B). In
addition to 17-β estradiol, the effect of selective ER modulators
(SERMs) such as tamoxifen and raloxifen was also investigated.
In the synoviocyte cell line used in the present study, tamoxifen
did not affectMMP-13 promoter activity at lower concentrations
(10− 12 M), and led to slight (approximately 10%) decreases in
MMP-13 promoter activity at higher concentrations (10− 8 M).
Raloxifen, at concentrations of 10− 8 M and 10− 12 M, led to
inhibition of the rabbit MMP-13 promoter activity by about 35–
40% in the presence of ER-α. As shown in Fig. 3B, in the HIG-
82 cells raloxifen led to less suppression of MMP-13 promoter
activity than was detected with 17-β estradiol.
3.5. Functional characterization of the promoter elements of
rabbit MMP-13 in response to ER-α and its agonist ligand,
17-β estradiol
The results of the previous experiments demonstrated that
MMP-13 promoter activity can be modulated differently by ER-
Fig. 2. (A and B) Effect of ER-α on the endogenous levels of MMP-13 in the HIG-82 cells. The mRNA levels for endogenous MMP-13 expressed prior to and after
transfection with ER-α in HIG-82 cell line were determined by RT-PCR. Rabbit synoviocytes (HIG-82), were either untransfected (control), or were transiently co-
transfected with (0.2–1 μg) of ER-α (pKCR2-ERα). After 24 h of transfection, total RNAwas extracted from the cells and analyzed by RT-PCR. Panel A: MMP-13
and β-actin PCR products as visualized with an ethidium bromide stained gel. Panel B: Quantity1 1-D analysis software (Biorad) software was used to determine band
densities. By normalizing to the levels of the β-actin housekeeping gene, relative mRNA levels for the endogenous MMP-13 gene were determined. Panel C: Effect of
increasing concentrations of ER-α on transfected MMP-13 promoter without treatment with any ligand. Rabbit synoviocytes (HIG-82), were transiently co-transfected
with the rabbit MMP-13 promoter construct (p370-Luc), ER-α (pKCR2-ERα), and the internal control plasmid, pRLSV40. Increasing concentrations of pKCR2-ERα
ranging from (0.1 to 4 μg) were used in this experiment. Cells transfected with p370-Luc alone were used as controls. Luciferase activity was expressed as the ratio of
p370-Luc firefly luciferase activity and the Renilla luciferase reporter activity. In the absence of exogenous ER-α, luciferase activity was 0.01 Units and in the presence
of 4 μg of ER-α construct, luciferase activity was 1.2 units, representing ∼120-fold increase in activity. Values represent the mean±S.E. for three determinations.
†p<0.001 as compared with p370-Luc activity in the absence of ER-α and without any ligand treatment.
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identify the specific elements of the MMP-13 promoter that play
a role in ER-α mediated regulation. Several deletion constructs
of varying lengths of the MMP-13 promoter were generated asdescribed earlier (See Fig. 3A). In order to characterize the role
of promoter elements of the rabbit MMP-13, DNA constructs
with various lengths of the promoter (p637-Luc, p370-Luc,
p151-Luc, p109-Luc, p73-Luc and p43-Luc) were transiently
Fig. 3. (A) Schematic representation of the cloned DNA constructs containing promoter elements of rabbit MMP13. The constructs p637, p370 and p151 contain all the
known key elements of rabbit MMP13 promoter region such as Runx domain (RD), p53, PEA-3 and AP-1 binding sites. The construct, p109, is missing the Runx
domain and all the other key elements are present. The p73 contains only the AP-1 promoter element and p43 is missing all the key elements. All the promoter
fragments were cloned into the vector, pGL2-Basic, which contains the promoterless Luciferase gene. (B) Effect of equivalent doses of agonists and antagonists of ER-
α on the activity of rabbit MMP-13 promoter in HIG-82 cells. Rabbit synoviocytes, HIG-82, were transiently co-transfected with rabbit MMP13 promoter construct
(p370-Luc), pKCR2-ER-α and internal control plasmid, pRLSV40. Cells were treated with two different concentrations of (10−8 M and 10−12) 17-β Estradiol,
(10−8 M and 10−12) Tamoxifen or (10−8 M and 10−12) Raloxifen for 24 h post-transfection. Luciferase activity was expressed as ratio of firefly luciferase activity and
Renilla luciferase reporter activity. Values represent the mean±S.E. for three determinations and are expressed as percentage of p370-Luc luciferase activity without
treatment with ligands. †p Value<0.005 when compared to the Control. ‡p Value<0.05 when compared to the Control.
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pRSV40L. In the presence of ER-α, the MMP-13 promoter
constructs exhibited varying degrees of activity proportional to
the presence and role of each regulatory site. Maximum activity
of the promoter was achieved when the MMP-13 promoter
construct contained all the known transcription factor binding
sites-the Runx, p53, PEA-3 and AP-1 sites. This has been
observed for luciferase activity levels in the p637-Luc, p370-
Luc and p151-Luc constructs (Fig. 4A).A∼21% reduction in luciferase activity was observed for the
p109-Luc when compared to the control p637-Luc, which
suggests that the Runx domain plays a minor role in the
activation of the MMP-13 promoter by ER-α. The p109-Luc
construct contains the AP-1, PEA-3 and p53 binding sites and is
only missing the Runx domain. In contrast, the absence of Runx
along with the PEA-3 and p53 binding sites led to a ∼53%
decrease in luciferase activity (p73-Luc) as compared to that
seen with the control p637-Luc construct (Fig. 4B). These
Fig. 4. Functional characterization of the promoter elements of rabbit MMP-13 in response to ER-α and its agonist, 17-β Estradiol. (A) Rabbit Synoviocytes, HIG-82,
were transiently co-transfected with deletion constructs of rabbit MMP13 promoter (p637-Luc, p370-Luc, p151-Luc, p109-Luc, p73-Luc and p43-Luc), ER-α
(pKCR2-ERα) and pRLSV40. One set of transfected cells were treated with 10−8 M 17-β estradiol for the duration of transfection. Luciferase activity was expressed as
the ratio of firefly luciferase activity and the Renilla luciferase reporter activity. Values represent the mean±S.E. for three determinations and are expressed as
percentage of p637-Luc luciferase activity without treatment with agonist or antagonists. †p<0.01 as compared with p637-Luc activity in the presence of ER-αwithout
any ligand treatment. ‡p<0.001 as compared with p637-Luc activity in the presence of ER-α with ligand treatment. ⁎p<0.01 as compared with p637-Luc activity in
the presence of ER-α with ligand treatment. ⁎⁎p<0.001 as compared with p637-Luc activity in the presence of ER-α with ligand treatment. ↔p<0.01 for deletion
mutants of MMP-13 in the presence and absence of the ligand.
725T. Lu et al. / Biochimica et Biophysica Acta 1762 (2006) 719–731results indicate that the presence of only the AP-1 transcription
factor binding site is sufficient for ER-α induced stimulation of
promoter activation. However, for maximal stimulation of the
MMP-13 promoter, the presence of the Runx, PEA-3 and p53
sites are also required. These studies further indicate that
complete absence of all the essential promoter elements (p43-
Luc) of rabbit MMP-13 leads to an approximately 90% decrease
in the activity of the promoter.
Treatment of cells transfected with MMP-13 constructs of
varying length and the ER-α construct plus 17-β estradiol led to
an ∼50% decrease in MMP-13 promoter activity, as observed
for the constructs p637-Luc, p370-Luc and p151-Luc, in the
presence of ER-α. The extent of depression of luciferase
activity shown in the presence of the p109-Luc construct is
approximately 5% lower than that exhibited by longer rabbit
MMP-13 promoters, when treated with 17-β estradiol. These
results indicate that the absence of the Runx domain in theMMP-13 promoter (p109-Luc) appears to have a minimal effect
on the repression by this ligand. The absence of Runx, p53 and
PEA-3 domains (p73-Luc) led to an increase in repression by
about 30% as compared to the repression shown in the controls
(p637-Luc). This suggests that presence of the AP-1 transcrip-
tion factor binding site alone is still sufficient to mediate the
effects of the ligand 17-β estradiol. Interestingly, the ratio of
decrease in the promoter activity of MMP-13 constructs of
different lengths when treated with 17-β estradiol remained
steady between 1.88 and 2.
3.6. AP-1 site of rabbit MMP-13 promoter acts in conjunction
with other regulatory elements in the presence of ER-α (±)
17–β Estradiol
To further clarify the role of the individual elements of the
MMP-13 promoter, the p370-Luc construct was used to
Fig. 5. Evidence that the AP-1 site in the rabbit MMP-13 promoter is critical for ER-α modulation of rabbit MMP-13 activity and its inhibition by 17-β Estradiol. (A)
Data showing the primary sites that were mutated by site directed mutagenesis in the different constructs. (B) HIG-82 cells were transiently co-transfected with wild-
type and site-directed mutant constructs of rabbit MMP-13 promoter in pGL2-Basic vector (WT370, M370A3, M370R2, M370A3R2, M370P2, M370A3P2,
M370A3P2R2 and WT43), ER-α (pKCR2-ERα) and internal control plasmid, pRLSV40. One set of transfected cells was treated with 10−8 M 17-β Estradiol after
transfection for a period of 24 h. Luciferase activity was expressed as the ratio of firefly luciferase activity and the Renilla luciferase reporter activity. Values represent
the mean±S.E. for three determinations and are expressed as percentage of p637-Luc luciferase activity without treatment with 17-β Estradiol. (C) Data showing
percentage decrease in luciferase activity for different mutant constructs. Site directed mutagenesis on AP-1 site leads to∼80% decrease in promoter activity indicating
that AP-1 site is the most essential mediator of ER-α action in the presence and absence of ligand. †p Value<0.05 when compared to the WT370 without ligand
treatment. ‡p Value<0.005 when compared to the WT370 without ligand treatment. •p Value<0.05 when compared to the WT370 with ligand treatment. ⁎p
Value<0.005 when compared to the WT370 with ligand treatment. ↔p Value<0.05 when compared for each sample (±) ligand.
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promoter. The HIG-82 cells were transiently co-transfected with
either the wild-type (WT370) or the site-directed mutant
constructs of the rabbit MMP-13 promoter along with ER-α
(pKCR2-ERα) and the internal control plasmid, pRLSV40. The
construct M370A3 contains mutations in the AP-1 site alone.
M370R2 has only the Runx domain mutated and M370P2 has
only the PEA-3 transcription factor binding site mutated. Both,
the AP-1 and Runx domain are mutated in the double mutant,
M370A3R2 and both AP-1 and PEA-3 sites are mutated in the
double mutant construct, M370A3P2. The mutant construct,
M370A3P2R2 has all the three sites (AP-1, PEA-3 and Runx
domain) mutated. One complete set of transfected cells were
further treated with 10− 8 M 17–β estradiol. The activity level of
cells transfected with wild type (WT370) was used as a control
for this experiment.
Site directed mutations in the Runx domain changed the
normal Runx site of (AACCACA) to (AGACACA). As shown
in Fig. 5B (lane 2) and C, a 14% decrease in the luciferase
activity was observed when only the Runx site was mutated
(M370R2) when compared to the activity levels of WT370 (Fig.
5B, lane 1). Mutations in the PEA-3 site which changed the
consensus sequence from AGGAAGC to AACAAGC
(M370P2), resulted in a 38% decrease in activity of the rabbit
MMP-13 promoter in the presence of ER-α (Fig. 5B (lane 3)).
The AP-1 site was mutated in two ways. In the construct,
m370A1, only one base was mutated and the consensus was
changed from TGACTCA to GGACTCA and in m370A3, two
bases were mutated to change the consensus to ACTCTCA. The
activity of the MMP-13 promoter decreased (∼76%) when two
sites were mutated in the AP-1 domain. However, even a single
mutation in the AP-1 site was sufficient to reduce the activity of
MMP-13 promoter (m370A1) by approximately the same
amount in the presence of ER-α (data not shown). The activity
levels for the mutant construct, m370A3 were similar to those
for m370A1, indicating that increasing the number of mutations
at this site does not decrease the MMP-13 promoter activity any
further. These results confirm the deletion studies which
indicated that the AP-1 site may be the most essential element
in the rabbit MMP-13 promoter for modulation by ER-α.
Subsequently, the effect of mutating two or three of these
sites together was examined. The rabbit MMP-13 promoter
activity, when both the Runx domain and AP-1 sites are
mutated, was approximately∼76% lower than that observed for
the wild type MMP-13 promoter (WT370) under the same
conditions (Fig. 5B Lane 5). Further, the activity levels of
M370A3R2 were comparable to the activity seen for the AP-1
mutant construct (M370A3) alone (compare lanes 4 and 5 of
Fig. 5B). Such findings confirm that the Runx domain does not
play a significant role in controlling the MMP-13 promoter
activity by ER-α. When mutations in the PEA-3 site and AP-1
site (M370A3P2) were examined together, the activity level of
MMP-13 was ∼ 85% lower than that observed for the WT370
promoter activity (Fig. 5B Lane 6). These results further
corroborate the observations regarding the MMP-13 promoter
activity levels for the single mutants (M370R2 or M370P2).
Specifically, that the PEA-3 mutation has a more detrimentaleffect on MMP-13 promoter activity than does the Runx domain
mutation (compare Lanes 2, 3 and 6 in Fig. 5B). Further, even
when all three sites, i.e. AP-1, PEA-3 and Runx (M370A3P2R2)
were mutated, the MMP-13 promoter activity was inhibited by
86%, which is nearly the same as that observed for the double
mutant (M370A3P2). These results indicate that AP-1 and
PEA-3 are likely the major elements in regulating the rabbit
MMP-13 promoter activity in response to ER-α.
The decrease in promoter activity in the presence of 17-β
estradiol was ∼57% for WT370. The repression of activity
observed for the construct M370R2, when treated with 17- β
estradiol, was only ∼4% less than the activity levels of WT370
with the ligand. These results again suggest that the Runx
domain is a minor player in the MMP-13 promoter for
mediating the effects of ER- α and its ligand, 17-β estradiol.
The decrease in promoter activity levels when the PEA-3 site
was mutated (M370P2) was approximately 12% when treated
with 17-β estradiol, and for M370A3 with the AP-1 site
mutated, was an ∼32% decrease in activity under the same
conditions. The double and triple mutants also exhibited
approximately 32–37% decreases in activity in the presence
of ligand and ER-α as compared to WT370 in the presence of
ligand. These results demonstrate the importance of the PEA-3
and AP-1 sites in mediating the effects of the ligand 17-β
estradiol.
4. Discussion
It is well known that the binding of steroid hormones to their
specific intracellular receptors modulate gene expression within
the hormone-responsive tissue. The results presented in this in
vitro study suggest that the alpha isoform of the ER can
modulate the activity of the MMP-13 promoter and this
influence is dependent upon the presence and absence of the
steroid hormone estrogen. Furthermore, other ER-α agonists or
antagonists such as tamoxifen and raloxifen also have varying
degrees of influence on the expression of the MMP-13
promoter. Analysis of the MMP-13 promoter through deletion
and site-directed mutagenesis studies have shown that regula-
tion of MMP-13 promoter activity by ER-α occurs primarily
through the AP-1 transcriptional regulatory site. However, for
full induction of MMP-13 promoter activity, other regulatory
sites such as Runx and PEA-3 also contribute to the activation
by ER-α.
The in vitro findings in this study indicate that MMP-13
promoter activity is elevated in the presence of ER-α when both
are transfected into the HIG-82 cell line. The HIG-82 cell line
used in this study was found to be devoid of detectable
endogenous ER using both western blot analysis and immuno-
histochemistry, thereby ruling out the influence of endogenous
ER-α on the MMP-13 promoter activity (see Fig. 1). The HIG-
82 cells originally determined to be ER negative became ER
positive after transfection with the ER-α plasmid construct,
indicating that the ER-α protein was being produced after
transfection into the HIG-82 cell line. Increasing amounts of
ER-α DNA (0–4 μg) led to an increase in the MMP-13 activity
as shown in Fig. 2A. Furthermore, the HIG-82 cell lines were
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which showed an increase in the presence of ER-α and
decreased when the transfected cells were treated with the
estrogenic ligand 17-β estradiol.
Several studies performed by different groups have estab-
lished that 17-β estradiol as an agonistic ligand of ER-α and
responsible for its transcriptional activation [29,30]. Binding of
the ligand, 17-β estradiol, to the ER leads to the formation of
receptor dimers and subsequent transcriptional control of the
target genes [31,32]. The present study showed that when the
ligand estradiol was added, the activity of the MMP-13
promoter decreased by about 50% in the presence of ER-α.
The decrease in rabbit MMP-13 promoter activity followed a
dose dependent pattern i.e. higher repression of promoter
activity is observed for higher concentration of estradiol (see
Fig. 3B). Increasing the length of treatment time with estradiol
from 12 to 24 h did not have a significant impact in further
decreasing the activity of the MMP-13 promoter (data not
shown).
The promoter of the MMP-13 gene is well characterized, and
it has the following cis–acting regulatory elements-TATA box,
AP-1 site, PEA-3 site, p53-site and the Runx domain [33,34].
Several MMP-13 promoter constructs of differing lengths were
cloned into the promoterless luciferase vector (pGL2) and used
in transfection of HIG-82 cell line along with ER-α. The results
demonstrate that maximal level of activity of the MMP-13
promoter is observed when the promoter constructs contains all
the cis-acting transcriptional regulatory elements (p637-Luc, p-
370-Luc and p151-Luc) in the presence of ER-α. The level of
activity observed for the promoter fragment p151-Luc, which
has only 151 bases upstream of the transcription initiation site,
is similar to the level of activity of p637-Luc or p370-Luc,
which has 637 and 370 bases of MMP-13 promoter. Thus, it
appears that approximately 151 base pairs of the promoter
region of the MMP-13 are sufficient for the majority of its
regulation in the presence of ER-α. This result further
corroborates the findings of Selvamurugan et al. [35,36], who
have shown that only 148 base pairs upstream of the rat MMP-
13 are required for its basal expression and activation by
parathyroid hormone. Previous studies by Winchester et al. [37]
have also shown that 148 base pairs of the upstream sequence,
which contains all the major regulatory elements, is the minimal
region required for the transcriptional activity of MMP-13 in
normal and differentiating osteoblasts of rats.
The action of the ER, in response to its ligand estrogen,
occurs through either estrogen response elements (EREs) or the
AP-1 site of the estrogen responsive genes [38]. ER can act via
the AP-1 site by binding to other promoter binding proteins
[38]. The classical estrogen response element is absent in the
MMP-13 promoter, although it does have the AP-1 site. To
delineate the promoter elements mediating the regulatory effect
of ER-α on the MMP-13 promoter, in the absence and presence
of estrogen agonists and antagonists, rabbit synoviocytes were
transfected with MMP-13 promoter deletion constructs along
with ER-α and the resulting promoter activity was examined in
the presence and absence of estradiol. The results suggest that
while AP-1 site alone contributes significantly (∼50%) to theMMP-13 promoter activity, other promoter sites such as the
Runx domain, p53 site and PEA-3, also play a modulating role
in mediating the effects of ER-α. Additionally, complete
absence of the Runx domain, p53, PEA-3 and AP-1 site (p43-
Luc) in the promoter of rabbit MMP-13 leads to very minimal
MMP-13 promoter activity. Interestingly, the luciferase activity
driven by the p109-Luc promoter, the p73-Luc or the p43-Luc
construct is decreased by 50% in the presence of the hormone
17-β estradiol when compared to its untreated control. Previous
studies have shown that AP-1 and Runx transcriptional
regulatory sites cooperatively interact to regulate MMP-13
expression in response to parathyroid hormone ([39,35],
reviewed in [5]) and this was also apparent in the current
studies.
In addition to using deletion promoter constructs of MMP-
13, point mutations were also introduced into different
regulatory sites on the MMP-13 promoter. The p370-Luc or
WT370 was used as the control for these experiments. There
was a ∼57% decrease in the activity of the WT 370 promoter
when ER-α and 17-β estradiol was present. Additionally, the
results show that when only the Runx domain of the promoter
had point mutations (M370R2) the promoter activity was
decreased by a modest (∼4%) in the presence of 17-β estradiol,
as compared to the wild type p370-Luc promoter activity in the
presence of the ligand and ER-α. The ratio of decrease (∼2.0) in
promoter activity was similar for both WT370 and M370R2 in
the presence of 17-β estradiol. Point mutations in the PEA-3 site
alone (M370P2) led to a 38% decrease in luciferase activity as
compared to the wild type 370 in the presence of ER-α, without
treatment with ligand. Once again luciferase activity was
decreased by approximately 31% for M370P2 in the presence of
ER-α and its ligand 17-β estradiol, as compared to its untreated
control. The luciferase activity was decreased by 76% in the
absence of estrogen, when constructs with only the AP-1 site
mutated (M370A1) and (M370A3) were used in transfection
experiment along with the ER-α. Since the luciferase activity
levels for constructs, M370A1 and M370A3, were not
significantly different in the presence of ER-α with or without
treatment with 17-β estradiol, one can conclude that a single
base mutation at the AP-1 site (M370A1) is sufficient to impact
the activity of the MMP-13 promoter. Increasing the number of
mutations at the AP-1 site (M370A3) did not lead to any further
decrease in the luciferase activity. Thus, one can conclude that
the primary effect of ER-α in the presence and/or absence of
ligand, on the activity of the MMP-13 promoter appears to be
mediated through the AP-1 site. The Runx domain plays a
smaller role than the PEA-3 site in mediating the effects of ER-
α in the absence and presence of ligand. Double mutant
constructs in which both AP-1 and Runx domain (M370A3R2)
are mutated showed a higher luciferase activity than those in
which AP-1 and PEA-3 have been mutated (M370A3P2 or
M370A1P2). The luciferase activity when the AP-1, PEA-3 and
Runx sites were simultaneously mutated was not significantly
different than that observed when the double mutant constructs
M370A3P2 , which has the PEA-3 and AP-1 site mutated, was
assessed. These results clearly indicate that AP-1 is the most
important regulatory site, followed by the PEA-3 and Runx sites
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the presence and absence of ligand.
Estrogen replacement therapy is often suggested as a way to
combat the onset of postmenopausal OA [40,41]. However,
conventional estrogen replacement therapy has been linked to
unacceptable health risks such as cancer because binding of the
hormone estrogen to its receptors can lead to dysregulated cell
proliferation. This has led to the development of designer
estrogens termed as Selective Estrogen Receptor Modulators
(SERMs) and these show evidence of both estrogenic and anti-
estrogenic properties, depending on the tissue type [42].
Tamoxifen and raloxifen are classified as anti-estrogenic ligands
which are capable of binding to ER [17], thereby preventing
estrogen from binding to its receptor. The binding of tamoxifen
to ER prevents estrogen-dependent cell proliferation in breast
tissues. However it can still lead to the development of uterine
cancer [43–45]. The role of tamoxifen has been paradoxical: it
can act as a partial agonist or as an antagonist of ER-α
depending on the cell type [46–48,31]. In the present study,
tamoxifen at low concentrations of (10− 12 M) did not have any
significant effect on MMP-13 promoter activity. However, in
the presence of higher concentration of tamoxifen (10− 8 M), the
MMP-13 promoter activity was decreased by 20% with respect
to its untreated control. Thus, tamoxifen appears to act as a
partial agonist of ER-α in the transfected rabbit synoviocytes.
Raloxifen is clinically prescribed for prevention and treatment
of post-menopausal osteoporosis and it is another alternative to
tamoxifen. Similar to 17-β estradiol, raloxifen also binds with
high affinity to ER-α although there are subtle differences in the
binding complexes between the two ligands and the receptor
[49].The results presented in this study demonstrate that MMP-
13 promoter activity decreased in the presence of raloxifen
(10− 8 M and 10− 12 M), but this drug was less effective than
estrogen (see Fig. 3).
The findings presented in this study may have significant
clinical relevance as they provide insight into a fundamental
relationship between estrogen loss and induction of an MMP
implicated in postmenopausal bone and cartilage diseases.
Menopause in women is characterized by estrogen deficiency
which in turn results in bone loss in a subset of these females.
Osteoporosis and osteoarthritis (OA) are the most common
musculoskeletal disabilities associated with declining estrogen
levels in women. OA is characterized by the degeneration of the
articular cartilage which leads to pain, stiffness and loss of joint
function [50]. Degradative events in articular cartilage involve
the breakdown of the components of the extracellular matrix by
the matrix degrading enzymes such as the matrix metallopro-
teinases (e.g.: MMP-1, MMP-3 and MMP-13). These protei-
nases may originate either from the synovium, as studies have
shown that MMPs tend to be elevated in the synovial fluid of
OA patients [51,52], or from the chondrocytes of the OA
cartilage [53–55]. Constitutive expression of human MMP-13
in hyaline cartilage tissue has been shown to lead to
osteoarthritis in mice [10]. Additionally, Li et al. [11] have
also shown that expression of MMP-13 mRNA and protein are
noticeably increased in the ovariectomized rat, suggesting that
MMP-13 may play an important role in estrogen deficiencyinduced conditions/diseases. However, in a separate study,
estrogen has been shown to decrease the expression of MMP-1,
but have no effect on the expression levels of MMP-13 in
osteoarthritic chondrocytes [24].
In summary, the findings presented here demonstrate that ER-
α can modulate the regulation of the MMP-13 promoter
differently in the presence and absence of SERMs, primarily
through the AP-1 binding site in the promoter. While the
conclusions derived from this study need to be further
corroborated via studies in an ovariectomized animal model,
this system can perhaps be used to assess the functional activity of
new therapeutic alternatives of estrogen before embarking on
animal studies. The findings presented in this studymay also have
clinical relevance in addition to the above discussed bone loss, as
abnormal expression of matrix metalloproteinases such as MMP-
13 is believed to involved in the cartilage degradation in OA and
the onset of OA in initiated following menopause when the
estrogen levels in the body decline, at least in a subset of females.
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